EFPIA Newsletter 08 December 2022

How Brussels can inject vigour into pharma sector     Nathalie Moll's letter to the FT   Nathalie Moll, EFPIA Director General, wrote to the Financial Times in response to their article “US subsidies for green technology ring alarm bells in EU capitals” (Report, November 21). "Your article resonated with the European research-based pharmaceutical industry. Competition from the US for high-tech investment is not new. In the 1990s, while half of all new treatments originated from Europe, that figure is now just one in five. In 2002, the US spent $2bn more than Europe on pharmaceutical R&D — today it is spending $25bn more. (...)" Read more →

News     06 December 2022 EU-China Biopharmaceutical Innovation Roundtable Strengthening cooperation and dialogue on health and innovation Read more →         05 December 2022 Post-code lottery in European diabetes care must be addressed, says EFPIA Innovation offers the potential to improve health outcomes and quality of life for people living with diabetes. EFPIA... Read more →

Podcasts     08 December 2022 Why is a therapeutics waiver extension different to the vaccine waiver? While the goals of ramping up production and improving access are valid ones, not only is a waiver extension not needed,... Read more →

Events     12 DEC 2022   Enhancing patient-centric outcome measures and clinical trials with Digital Health... Virtual event Last chance to register! Learn more →       12 DEC 2022   How can we reduce premature and preventable deaths caused by cardiovascular diseases... Brussels Learn more →

	12 DEC 2022			IHI Call Days - Call 3 Virtual event Join the webinar to get information on how to apply and to meet potential partners for consortia. Learn more →

	24 JAN 2023			Launch event of the RETHINKING Alzheimer's disease White Paper Virtual event Registrations are now open. Learn more →

‘Rare Disease Moonshot’ launched today Scaling-up public-private partnerships to accelerate research into world’s rarest diseases A new initiative to boost research and development into rare and paediatric diseases was launched today at the European Health Summit. The ‘Rare Disease Moonshot’ is a commitment and collaboration between seven organisations to break down the barriers to finding new treatments and cures for the world’s rarest and severe conditions which currently have no therapeutic options, and which often affect the youngest patients.

What we are reading BEAM Alliance’s reaction to the ‘non-paper’ issued by 14 Member states on antimicrobial market... 07 December 2022  (BEAM Alliance) Read more → A Viable European Union Medicines Regulatory System Must be a Cornerstone for Innovation in... 05 December 2022  (DIA Global Forum) Read more → Impact of a waiver of intellectual property rights for COVID-19 therapeutics 05 December 2022  (IFPMA) Read more →

About the EFPIA newsletter The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55 Communications@efpia.eu ▶ in

EFPIA 2026 All rights reserved  ·  Disclaimer  ·  Unsubscribe